EyeBio has completed a round of Series A funding, totaling $65 million, according to a press release.
The company was founded in August 2021 with the goal of developing a new generation of therapies for sight-threatening eye diseases.
“Advances in research are revealing new opportunities to translate science into solutions that serve patients with eye diseases who have urgent and unaddressed medical needs,” David Guyer, MD, co-founder, president and CEO of EyeBio, said in the release. “Patients and physicians deserve new and better solutions, which is why this team of serial